APM
UTHR icon

Avidity Partners Management’s United Therapeutics UTHR Stock Holding History

Avidity Partners Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,800
Closed -$5.18M – 82
2025
Q1 		$5.18M Buy
+16,800
New +$5.76M 0.99% 37
2024
Q3 		– Sell
-110,000
Closed -$35M – 102
2024
Q2 		$35M Sell
110,000
-107,000
-49% -$28.3M 1.49% 26
2024
Q1 		$49.8M Sell
217,000
-20,202
-9% -$4.56M 1.61% 21
2023
Q4 		$52.2M Buy
+237,202
New +$54.7M 1.9% 19
2023
Q1 		– Sell
-785,500
Closed -$218M – 93
2022
Q4 		$218M Sell
785,500
-184,700
-19% -$46.6M 4.73% 3
2022
Q3 		$203M Buy
970,200
+244,600
+34% +$54.7M 4.13% 3
2022
Q2 		$171M Buy
725,600
+6,654
+0.9% +$1.35M 3.93% 8
2022
Q1 		$129M Buy
718,946
+183,946
+34% +$35M 2.69% 13
2021
Q4 		$116M Buy
535,000
+184,000
+52% +$36.1M 2.45% 12
2021
Q3 		$64.8M Buy
351,000
+114,600
+48% +$22.6M 1.44% 25
2021
Q2 		$42.4M Buy
+236,400
New +$45M 1.15% 32

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Avidity Partners Management's UTHR Position: Q2 2025 in Review

Avidity Partners Management sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 16,800 shares — an estimated $5.18M sold.

Avidity Partners Management first reported a position in UTHR in Q2 2021 and held it in 11 quarters. The position peaked at $218M in Q4 2022. 671 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • Avidity Partners Management reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 16,800 United Therapeutics shares in Q2 2025, an estimated $5.18M.
  • Avidity Partners Management first reported a position in United Therapeutics in Q2 2021 and held it in 11 quarters.
  • Avidity Partners Management's United Therapeutics position peaked at $218M in Q4 2022.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.